TrialKPL-301 for Subjects With Giant Cell Arteritis
Trial details
- Registry ID
- NCT03827018
- Phase
- Phase 2
Drug research
mavrilimumab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as CAM3001; KPL-301
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| KPL-301 for Subjects With Giant Cell ArteritisNCT03827018 | Kiniksa Pharmaceuticals, Ltd. | Phase 2 | Completed | 2020-08-13Actual |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationNCT04447469 | KNSA | Phase 2, Phase 3 | Completed | 2021-11-12Actual |
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Trial details
- Registry ID
- NCT04447469
- Phase
- Phase 2, Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |